Gliosarcoma

Gliosarcoma
Other namesSarcomatous glioblastoma
Micrograph showing a gliosarcoma. Elastic van Gieson's stain.
SpecialtyNeuro-oncology
Usual onsetBetween 40 and 60 years old
PrognosisFive-year survival rate: 5.6%
Frequency~215 new diagnoses per year (United States)

Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain cells, as opposed to the neural brain cells. Gliosarcoma is a malignant cancer, and is defined as a glioblastoma consisting of gliomatous and sarcomatous components. Primary gliosarcoma (PGS) is classified as a grade IV tumor and a subtype of glioblastoma multiforme in the 2007 World Health Organization classification system (GBM). Because of a lack of specific and clear diagnostic criteria, the word "gliosarcoma" was frequently used to refer to glial tumours with mesenchymal properties, such as the ability to make collagen and reticulin.

It is estimated that approximately 2.1% of all glioblastomas are gliosarcomas. Although most gliomas rarely show metastases outside the cerebrum, gliosarcomas have a propensity to do so, most commonly spreading through the blood to the lungs, and also liver and lymph nodes.

They most commonly present in the temporal lobe and frontal lobe.

Pathogenesis

Early reports claimed that the hyperplastic blood vessels that are frequently present in high grade gliomas underwent neoplastic change to become the sarcomatous components. Feigin's early reports components of perivascular sarcomatous and hyperplastic arteries in gliosarcoma offered evidence for the "collision tumor" hypothesis. Also, Studies demonstrating the sarcomatous component's histological sensitivity to markers of vascular endothelium such factor CD34, von Willebrand factor, and VIII supported this theory. An alternative view that has recently gained support suggests that both gliosarcoma components have a monoclonal origin, with the sarcomatous component deriving from abnormal differentiation of malignant gliomal mesenchyma. First, gliomatous and sarcomatous components were shown to have similar p53 alterations by Biernat and colleagues. In both tumor regions, Reis and colleagues found similar nuclear accumulation of p53, deletion of p16, mutations of PTEN, and amplifications of CDK4. Other scientists then noted that both gliosarcoma components had similar genetic changes and chromosomal abnormalities of the kind often seen in GBM.

Clinical characteristics

Gliosarcoma is rare; incidence ranges from 1.8 to 2.8 percent lower than that of GBMs. PGS affects persons in their 6th to 7th years of life, and it is much more frequent in males than in females (with 1.4–1.8:1 ratio). Depending on where the tumor is located, the reported presenting signs and symptoms, such as aphasia, headaches, hemiparesis, seizures, and cognitive loss, are similar with those of a fast developing intracranial tumor. Many researchers have come to the conclusion that these tumors are clinically identical to GBM due to their clinical similarities.

Imaging

On CT imaging, the lesions might show as Well-defined high-density lesion edges and homogeneous enhancement, replicating the meningioma appearance, or as lesions with large necrotic regions and GBM-like heterogeneous contrast enhancement. Marked peritumoral edema is a characteristic and frequent hallmark of gliosarcomas observed on MRI.

Metastasis

GBM and other cerebral gliomas rarely metastasize outside the brain. Numerous authors described incidences of metastatic foci that mixed gliomatous and sarcomatous components, while others reported metastatic foci that were entirely composed of the sarcomatous component. Most gliosarcoma extracranial metastases are found in the lung and liver, but there have been reports of metastases elsewhere as well, including evidence of intramedullary metastases to the cervical spine.

Treatment

Tumor removal, postoperative radiation treatment, and chemotherapy with nitrosureas, misonidazole, dacarbazine, temozolomide, doxorubicin, vincristine, cisplatin, mithramycin, ametophterin, thalidomide, or irinotecan have all been recorded as treatment options for gliosarcoma and radiotherapy with temozolomide.

Prognosis

PGS has a poor prognosis, a prognosis of median survival of 4 months in untreated individuals. The National Cancer Institute states that the relative five-year survival rate of gliosarcoma is only 5.6%.

References

  1. ↑ "Gliosarcoma: Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Archived from the original on 13 July 2019. Retrieved 13 July 2019.
  2. 1 2 3 4 "Gliosarcoma Diagnosis and Treatment". National Cancer Institute. 17 September 2018. Archived from the original on October 11, 2021. Retrieved March 8, 2023.
  3. ↑ Ayadi L, Charfi S, Khabir A, Kalle R, Sellami A, Makni S, et al. (March 2010). "[Cerebral gliosarcoma: clinico-pathologic study of 8 cases]". La Tunisie Médicale (in French). 88 (3): 142–6. PMID 20415184.
  4. ↑ Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (August 2007). "The 2007 WHO classification of tumours of the central nervous system". Acta Neuropathol. 114 (2): 97–109. doi:10.1007/s00401-007-0243-4. PMC 1929165. PMID 17618441.
  5. ↑ Stroebe H (1895). "Ueber Entstehung und Bau der Gehirnglioma". Beitr Pathol Anat Allg Pathol. 19: 405–486.
  6. 1 2 Feigin IH, Gross SW (1955). "Sarcoma arising in glioblastoma of the brain". Am J Pathol. 31 (4): 633–53. PMC 1942557. PMID 14388124.
  7. ↑ Beaumont TL, Kupsky WJ, Barger GR, Sloan AE (May 2007). "Gliosarcoma with multiple extracranial metastases: case report and review of the literature". Journal of Neuro-Oncology. 83 (1): 39–46. doi:10.1007/s11060-006-9295-x. PMID 17171442. S2CID 13171064.
  8. ↑ Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G (September 1998). "Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results". J Neurosurg. 89 (3): 425–30. doi:10.3171/jns.1998.89.3.0425. PMID 9724117.
  9. ↑ Parekh HC, O'Donovan DG, Sharma RR, Keogh AJ (April 1995). "Primary cerebral gliosarcoma: report of 17 cases". Br J Neurosurg. 9 (2): 171–8. doi:10.1080/02688699550041511. PMID 7632363.
  10. ↑ Meis JM, Martz KL, Nelson JS (May 1991). "Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases". Cancer. 67 (9): 2342–9. doi:10.1002/1097-0142(19910501)67:9<2342::aid-cncr2820670922>3.0.co;2-b. PMID 1849447.
  11. ↑ Feigin I, Allen LB, Lipkin L, Gross SW (1958). "The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation". Cancer. 11 (2): 264–77. doi:10.1002/1097-0142(195803/04)11:2<264::aid-cncr2820110207>3.0.co;2-d. PMID 13511345.
  12. ↑ McComb RD, Jones TR, Pizzo SV, Bigner DD (September 1982). "Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma". J Neuropathol Exp Neurol. 41 (5): 479–89. doi:10.1097/00005072-198209000-00001. PMID 6286891.
  13. ↑ Slowik F, Jellinger K, Gaszó L, Fischer J (1985). "Gliosarcomas: histological, immunohistochemical, ultrastructural, and tissue culture studies". Acta Neuropathol. 67 (3–4): 201–10. doi:10.1007/BF00687802. PMID 4050334.
  14. ↑ Wharton SB, Whittle IR, Collie DA, Bell HS, Ironside JW (2001). "Gliosarcoma with areas of primitive neuroepithelial differentiation and extracranial metastasis". Clin Neuropathol. 20 (5): 212–8. PMID 11594506.
  15. ↑ Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME (September 1995). "Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells". J Neuropathol Exp Neurol. 54 (5): 651–6. doi:10.1097/00005072-199509000-00006. PMID 7666053.
  16. ↑ Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H (February 2000). "Genetic profile of gliosarcomas". Am J Pathol. 156 (2): 425–32. doi:10.1016/S0002-9440(10)64746-3. PMC 1850048. PMID 10666371.
  17. ↑ Actor B, Cobbers JM, Büschges R, Wolter M, Knobbe CB, Lichter P, Reifenberger G, Weber RG (August 2002). "Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components". Genes Chromosomes Cancer. 34 (4): 416–27. doi:10.1002/gcc.10087. PMID 12112531.
  18. ↑ Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A, Raap AK, Scheithauer BW, Jenkins RB (September 1996). "The glial and mesenchymal elements of gliosarcomas share similar genetic alterations". J Neuropathol Exp Neurol. 55 (9): 973–81. doi:10.1097/00005072-199609000-00004. hdl:2066/23093. PMID 8800093.
  19. 1 2 3 Lutterbach J, Guttenberger R, Pagenstecher A (October 2001). "Gliosarcoma: a clinical study". Radiother Oncol. 61 (1): 57–64. doi:10.1016/s0167-8140(01)00415-7. PMID 11578729.
  20. ↑ Machuca TN, Prevedello DM, Pope LZ, Haratz SS, Araújo JC, Torres LF (September 2004). "Gliosarcoma: report of four cases with immunohistochemical findings". Arq Neuropsiquiatr. 62 (3A): 608–12. doi:10.1590/s0004-282x2004000400008. PMID 15334217.
  21. ↑ Lee YY, Castillo M, Nauert C, Moser RP (1985). "Computed tomography of gliosarcoma". AJNR Am J Neuroradiol. 6 (4): 527–31. PMC 8335194. PMID 3927668.
  22. ↑ Maiuri F, Stella L, Benvenuti D, Giamundo A, Pettinato G (February 1990). "Cerebral gliosarcomas: correlation of computed tomographic findings, surgical aspect, pathological features, and prognosis". Neurosurgery. 26 (2): 261–7. doi:10.1227/00006123-199002000-00013. PMID 2308674.
  23. ↑ Ehrenreich T, Devlin JF (October 1958). "A complex of glioblastoma and spindle-cell sarcoma with pulmonary metastasis". AMA Arch Pathol. 66 (4): 536–49. PMID 13582394.
  24. ↑ Garret R (1958). "Glioblastoma and fibrosarcoma of the brain with extracranial metastases". Cancer. 11 (5): 888–94. doi:10.1002/1097-0142(195809/10)11:5<888::aid-cncr2820110504>3.0.co;2-t. PMID 13585341.
  25. ↑ Smith DR, Hardman JM, Earle KM (August 1969). "Contiguous glioblastoma multiforme and fibrosarcoma with extracranial metastasis". Cancer. 24 (2): 270–6. doi:10.1002/1097-0142(196908)24:2<270::aid-cncr2820240210>3.0.co;2-5. PMID 4307749.
  26. ↑ Gjerdrum LM, Bojsen-Møller M (April 1999). "October 1998--61 year old male with brain tumor and oral, lung, and palpebral masses". Brain Pathol. 9 (2): 421–2. PMID 10219754.
  27. ↑ Ojeda VJ, Sterrett GF (April 1984). "Cerebral gliosarcoma, pulmonary adenoid-cystic carcinoma, and pulmonary metastatic gliosarcoma: report of an untreated case". Pathology. 16 (2): 217–21. doi:10.3109/00313028409059108. PMID 6087260.
  28. ↑ Weaver D, Vandenberg S, Park TS, Jane JA (September 1984). "Selective peripancreatic sarcoma metastases from primary gliosarcoma. Case report". J Neurosurg. 61 (3): 599–601. doi:10.3171/jns.1984.61.3.0599. PMID 6747700.
  29. ↑ Cerame MA, Guthikonda M, Kohli CM (September 1985). "Extraneural metastases in gliosarcoma: a case report and review of the literature". Neurosurgery. 17 (3): 413–8. doi:10.1227/00006123-198509000-00003. PMID 4047352.
  30. ↑ Slowik F, Balogh I (1980). "Extracranial spreading of glioblastoma multiforme". Zentralbl Neurochir. 41 (1): 57–68. PMID 6258355.
  31. ↑ Matsuyama J, Mori T, Hori S, Nakano T, Yamada A (October 1989). "[Gliosarcoma with multiple extracranial metastases. Case report]". Neurol Med Chir (Tokyo) (in Japanese). 29 (10): 938–43. doi:10.2176/nmc.29.938. PMID 2482946.
  32. ↑ Yokoyama H, Ono H, Mori K, Kishikawa M, Kihara M (December 1985). "Extracranial metastasis of glioblastoma with sarcomatous component". Surg Neurol. 24 (6): 641–5. doi:10.1016/0090-3019(85)90122-3. PMID 2997942.
  33. ↑ Witwer BP, Salamat MS, Resnick DK (November 2000). "Gliosarcoma metastatic to the cervical spinal cord: case report and review of the literature". Surg Neurol. 54 (5): 373–8, discusiion 378–9. doi:10.1016/s0090-3019(00)00315-3. PMID 11165614.
  34. ↑ Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J (March 2007). "Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study". Am J Surg Pathol. 31 (3): 351–62. doi:10.1097/01.pas.0000213378.94547.ae. PMID 17325476.
  35. ↑ Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (March 2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. doi:10.1056/NEJMoa043330. PMID 15758009.
  36. ↑ Kozak KR, Mahadevan A, Moody JS (April 2009). "Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome". Neuro Oncol. 11 (2): 183–91. doi:10.1215/15228517-2008-076. PMC 2718990. PMID 18780813.
  37. ↑ Morantz RA, Feigin I, Ransohoff J (October 1976). "Clinical and pathological study of 24 cases of gliosarcoma". J Neurosurg. 45 (4): 398–408. doi:10.3171/jns.1976.45.4.0398. PMID 956876.

Public Domain This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.